Armis Biopharma

Armis Biopharma is tackling the global antimicrobial resistance (AMR) crisis with its Veriox® platform, a proprietary topical antimicrobial/antitoxin. The technology aims to deliver high local concentrations of active agent with low systemic exposure, targeting a broad spectrum of pathogens including Gram-positive and Gram-negative bacteria, viruses, and fungi. The company is pre-revenue and in the preclinical development stage, focusing on creating products for wound care and surface decontamination to reduce infection severity and healthcare costs.

Patented Veriox® Technology, a proprietary peracid/hydrogen peroxide-based non-systemic antimicrobial/antitoxin platform for localized application. It claims broad-spectrum activity against bacteria (Gram+/Gram-), viruses, fungi, and toxins with a novel mechanism aimed at reducing resistance development.

Armis faces competition from large medtech companies in wound care (e.g., 3M, Smith & Nephew), established disinfectant makers, and numerous biotechs developing novel systemic and topical antibiotics. Differentiation hinges on proving Veriox®'s superior resistance profile and cost-effectiveness versus existing peroxygen-based disinfectants and antibiotics.